Clene

Clene FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Clene (CLNN) as of Nov 16, 2026 is 71.01 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 54.16 % — a change of 31.10% (higher).

FCF Conversion

71.01 %

YoY

31.10%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Clene is 2025 71.01 % . FCF Conversion Rate (FCF/EBITDA) of Clene was 2024 54.16 % . It decreases by 31.10% higher compared to the previous year.

The Clene FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
345.23 USD
Jan 1, 2019
83.51 USD
Jan 1, 2020
100.20 USD
Jan 1, 2021
369.16 USD
Jan 1, 2022
147.70 USD
Jan 1, 2023
61.61 USD
Jan 1, 2024
54.16 USD
Jan 1, 2025
71.01 USD
The Clene FCF Conversion history
YEARFCF ConversionYoY
71.01 %+31.10%
54.16 %-12.09%
61.61 %-58.29%
147.70 %-59.99%
369.16 %+268.41%
100.20 %+19.99%
83.51 %-75.81%
345.23 %—
0.00—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Clene Stock analysis

What does Clene do? Clene Inc develops therapeutic products for neurodegenerative diseases, focusing on targeting energetic failure as a root cause. Its primary product CNM-Au8 is an oral suspension of gold nanocrystals designed to restore neuronal health by enhancing energy production and utilization. The company also develops CNM-ZnAg, a spectrum antiviral and antibacterial agent containing zinc and silver ions for infectious disease treatment and immune support, and CNM-AgZn17, a gel polymer suspension of zinc and silver for wound healing and infectious disease management. These products are intended for clinical development and eventual commercialization in the pharmaceutical market. Clene's target customers are patients suffering from neurodegenerative diseases and infectious conditions requiring antiviral, antibacterial, or wound healing solutions. The company's products aim to address unmet medical needs in these therapeutic areas by leveraging innovative nanocrystal and ion-based technologies. The firm operates within the biopharmaceutical sector, developing treatments that focus on cellular energy processes to provide neuroprotection and remyelination. The company generates revenue through the development and potential future commercialization of its drug candidates. CNM-Au8 targets neurodegenerative diseases by addressing energetic failure, while CNM-ZnAg and CNM-AgZn17 focus on infectious disease treatment and wound healing applications. These products are in clinical development stages, with the company seeking to advance them toward regulatory approval and market entry. Clene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Clene stock

FCF Conversion Rate (FCF/EBITDA) of Clene is 71.01 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Clene changed from 54.16 % to 71.01 %, representing a 31.10% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Clene since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Clene with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Clene

All Key Metrics — Clene